Describing connections to substance use disorder treatment from a medical monitoring program servicing the homeless by Leung, Brandon
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2020
Describing connections to
substance use disorder treatment



















DESCRIBING CONNECTIONS TO SUBSTANCE USE DISORDER  
 
TREATMENT FROM A MEDICAL MONITORING PROGRAM 
 



















Submitted in partial fulfillment of the 
 
requirements for the degree of 
 









































© 2020 by 
 BRANDON LEUNG 










First Reader   
 Jessie Gaeta, M.D., MPH 
 Associate Professor of Medicine 
 Chief Medical Officer 






Second Reader   
 Susan Keyes, DrPH, RN 
 Director of Harm Reduction 







I would like to thank my two research advisors, Jessie Gaeta and Susan Keyes, for all the 
effort and patience it took to complete this project. I would like to thank all current and 
former SPOT staff members, especially Courtney Kenney who spent many hours helping 
to clean up the SPOT database and de-duplicate participant charts; thanks to Caitlin 
Pollard for describing SPOT operations and helping me brainstorm what factors to study. 
Big thanks to Melanie Racine for helping me export the data, and Dmitriy Brin for 
helping with the de-duplication. Thank you to Liz Lewis and Erica Wong for teaching me 
how to manage data in Microsoft Excel, and another thanks to Erica for advising me on 
the statistical analysis. Thank you to Vijendra Ramlall for advising me on study design. 
Finally, I would like to thank my supervisor Julie Jones for allowing me to be flexible 




DESCRIBING CONNECTIONS TO SUBSTANCE USE DISORDER 
TREATMENT FROM A MEDICAL MONITORING PROGRAM 
SERVICING THE HOMELESS 
BRANDON LEUNG 
ABSTRACT 
Introduction: Drug overdose death is now the leading cause of mortality among 
homeless adults in Boston, with opioids implicated in a majority of those deaths. Harm 
reduction interventions help minimize the risks associated with substance use, and are 
critical in supporting individuals with substance use disorder. Medical monitoring 
programs are an effective harm reduction strategy that work to prevent fatal drug 
overdoses and keep people safe while still actively using. 
Methods: Visit data from the Supportive Place for Observation and Treatment (SPOT) 
was compiled and analyzed. The two measures of interest were the count of referrals to 
substance use disorder treatment and the count of visits prior to the first referral to 
treatment. Chi-square tests of independence, odds ratios, and binary logistic regression 
models were used to describe the association between factors of interest and referrals to 
substance use disorder treatment.  
Results: Gender and age did not show any significant association to a connection to 
treatment. Overdose history (Adjusted Odds Ratio 6.59), reported stimulant use (AOR 
2.59), and documented health or harm reduction education (AOR 5.14) were all 
associated with increased odds of being referred to substance use disorder treatment. 
Heavy sedation (AOR 0.55) was associated with decreased odds of a treatment referral. 
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When examining factors associated with rapid connection to treatment, male gender (OR 
1.87) was associated with increased odds, while overdose history (AOR 0.42) was 
associated with decreased odds. 
Discussion: The two most impactful factors associated with increased odds of connecting 
to substance use disorder treatment were reported overdose history and documented 
education. Both of these factors suggests that a strength of SPOT is its ability to form and 
maintain meaningful connections with participants. One way that SPOT could improve 
referral outcomes would be to increase its ability to engage participants, such as through 
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The Present Opioid Crisis 
In the United States, there is an average of 130 opioid overdose deaths each day. 
Nationally, opioids are responsible for nearly 70% of drug overdose deaths.1 The state of 
Massachusetts experiences an average of five opioid overdose deaths each day, with an 
estimated 2,033 in the year 2018.2 A recent study examining mortality among adults 
receiving care at Boston Health Care for the Homeless Program (BHCHP) revealed that 
homeless adults in Boston account for a disproportionally high percentage of drug 
overdose deaths in Massachusetts.3 Despite their cohort only making up 0.3% of the 
state’s adult population, it accounted for 5% of the drug overdose deaths among 
Massachusetts adults in 2003 to 2008. Among adults age 25-44, drug overdose accounted 
for 1/3 of deaths, with opioids implicated in 81% of overdose deaths. This study 
highlighted the changing mortality landscape among homeless adults, which previously 
attributed HIV infection as the leading cause of death among 25 to 44-year-olds. 
Another observed change is the rise of fentanyl among people who use drugs 
(PWUD). While the incidence of opioid overdose deaths in Massachusetts has remained 
stable since 2016, the presence of fentanyl has steadily increased. Of the opioid overdose 
deaths in 2018 where a toxicology screen was available, 89% screened positive for 
fentanyl, versus 75% in 2016,2 indicating an increased risk of overdose when fentanyl is 
present. The onset of symptoms may appear within seconds to minutes, with some 
accounts describing loss of consciousness before the syringe used to inject can be 
removed from the injector’s arm.4 Analysis done by the Centers for Disease Control 
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(CDC) and the Drug Enforcement Administration (DEA) found that the increased 
presence of fentanyl can be attributed to illicitly made fentanyl (IMF).5 The DEA report 
shows that in 2014, the number of fentanyl drug seizures increased nearly 7-fold from the 
previous year. The state of Massachusetts had a reported 630 drug seizures, the second 
highest in the nation. Reporting also found drug distributors often mix IMF with heroin, 
cocaine, and other illicitly used drugs, and not always to the knowledge of the consumer. 
The high likelihood of unintentional fentanyl ingestion places PWUD at greater risk of 
overdose.  In fact, random sampling of drugs performed by a harm reduction agency in 
Boston found that packets of drugs sold as heroin often contained fentanyl.6  
Along with fentanyl, there is also the danger of unintentional carfentanil 
consumption. Carfentanil is a synthetic opioid used as a large animal tranquilizer, thus it 
is one hundred times more potent than fentanyl.7 Carfentanil may be introduced into drug 
samples through cross-contamination or intentional adulteration by illicit drug 
manufacturers. Even the consumption of a small amount could prove fatal. The DEA 
noted an alarming increase in the prevalence of carfentanil within the illicit drug market, 
prompting them to release a public safety announcement in September 2016.8  
Other substances have also been implicated in tandem with opioids in some 
opioid overdose deaths, including cocaine, amphetamines, and benzodiazepines.2 
Anecdotally, those who work in the substance use field may refer to a medication 
“cocktail” taken with an opioid, which usually consists of Klonopin, clonidine, 
gabapentin, and promethazine. While PWUD report using these four medications and 
others, it is not always clear whether they are using the actual medication or a counterfeit 
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pill made out of fentanyl or other sedating medications. An unpublished retrospective 
study conducted by BHCHP examining the vital signs of individuals who reported taking 
the cocktail, or varying combinations of its components, described a physiological 
presentation distinct from pure opioid overdose. These individuals will present with high 
levels of sedation, but will not have the dramatic response to Narcan as seen with a pure 
opioid overdose. The increasing presence of this polysubstance overdose further 
complicates the substance use landscape. Individuals found unresponsive on the street or 
presenting to the emergency department may not be overdosing from just opioids, if at 
all. Combined with the change in mortality among individuals experiencing homelessness 
and the increase risk of fentanyl and carfentanil exposure, the need for greater substance 
use and mental health services in Massachusetts is greatly underscored. One of BHCHP’s 
missions is to fill these gaps in services. 
 
Boston Health Care for the Homeless Program 
 Boston Health Care for the Homeless Program provides health and wellness 
services at over sixty locations in the greater Boston area.9 The program is staffed by 
hundreds of multidisciplinary clinical and administrative staff, including physicians, 
psychiatrist, nurse practitioners, physician’s assistants, clinical social workers, registered 
nurses, and more.9 Its headquarters, along with its medical respite facility, the Barbara 
McInnis House (BMH), is located on the corner of Massachusetts Avenue and Albany 
Street in Boston’s South End neighborhood. This places BHCHP in the geographic center 
of a cluster of services including homeless shelters, methadone clinics, a syringe service 
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program (SSP), and a detoxification and treatment center (detox) (Figure 1). The Access, 
Harm Reduction, Overdose Prevention and Education (AHOPE) program is a SSP 
located adjacent to BHCHP.10 In the same building as AHOPE is Providing Access to 
Addictions Treatment, Hope and Support (PAATHS), a program that helps individuals 
coordinate substance use disorder (SUD) treatment.11 Health Care Resource Center and 
Boston Comprehensive Treatment Center are both organizations that provide methadone 
maintenance treatment (MMT).12,13 Rosie’s Place is a privately run day center and 
homeless shelter for women.14 The Boston Public Health Commission (BPHC) operates 
two homeless shelters in the area, Woods Mullen Shelter for women, and Southampton 
Street Shelter for men.15 On a lot next to the Southampton Street Shelter, the BPHC runs 
the Engagement Center, a sheltered space for individuals to spend the day and access 






Figure 1. Map of services in the area surrounding Boston Health Care for the Homeless Program (1). Included are 
Boston Medical Center (2), AHOPE and PAATHS (3), Woods Mullen Shelter and Boston Treatment Center (4), Health Care 
Resource Center (5), Southampton Street Shelter (6), Rosie’s Place (7), Boston Comprehensive Treatment Center (8), and the 




 BHCHP provides healthcare services at all three of the BPHC locations. The large 
concentration of services in this area draws in PWUD, individuals seeking SUD 
treatment, drug traffickers, and individuals experiencing homelessness. This has led the 
media to unceremoniously dub the area “Methadone Mile”.17 However, those who work 
towards mitigating the stigma surrounding substance use prefer the title “Recovery 
Road”.18 Within this square mile exists a precarious relationship between PWUD, law 
enforcement, local businesses and residents, and health care professionals.  
 The tension surrounding Recovery Road came to surface during Mayor Martin 
Walsh’s “Operation Clean Sweep”, which further complicated the area’s opioid problem. 
Operation Clean Sweep was a large-scale police operation targeting an encampment of 
people living on Atkinson Street opposite the Southampton Street Shelter (Figure 1). 
Internal reports from BHCHP staff working at the shelter and Engagement Center noted 
that the Atkinson Street encampment was abundant with drug use, drug trafficking, and 
drug overdose and other medical emergencies. At the height of the encampment’s 
volume, BHCHP staff was responding to numerous drug overdoses each day. On August 
1st, 2019, an altercation occurred involving a correction officer and individuals from the 
encampment.19 The Mayor’s office responded swiftly by sending the Boston Police 
Department to clear out all residents, dispose of personal effects and arrest any person 
with an outstanding warrant. Over the next several weeks, police maintained a continuous 
presence to assure that the area was kept clear of homeless persons. The aftermath of this 
operation saw the encampment’s inhabitants disperse; however, a number of individuals 
migrated one or two streets over, to the immediate vicinity of BHCHP’s headquarters.  
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The formation and disbandment of the Atkinson Street encampment disrupted an 
environment already ravaged by the changing mortality landscape and arrival of fentanyl 
and carfentanil. However, BHCHP’s presence in the area poised the organization to step 
up and address the growing need for services. On top of providing traditional outpatient 
based addiction treatment (OBAT), they provide other supportive services such as 
housing, dental care, and harm reduction.9 The work done by BHCHP helps individuals 
access the recovery services pathway utilizing a very low barrier approach.   
 
Substance Use Disorder Continuum of Care 
 When an individual is seeking SUD treatment, they generally follow a continuum 
of care that leads them from acute treatment services (ATS) to outpatient services (Figure 
2). Early in the continuum are acute treatment services and clinical stabilization services 
(CSS), which focus on treating withdrawal symptoms and physically stabilizing the 
individual.20 Transitional support services (TSS) are still clinically managed but to a 
lesser extent than a CSS.20 A TSS is meant to help an individual maintain sobriety as they 
plan treatment further down the continuum. Once that has been accomplished, the 
individual is eligible for residential treatment programs such as halfway houses, followed 
by a sober home.20 In those settings, the focus is on learning behavior and skills to 
support their recovery. Once an individual is living independently, they are able to access 
outpatient services such as peer recovery groups and substance use counseling. 
Throughout the continuum, access to medication assisted treatment (MAT), mental health 
services, housing services, primary care, and harm reduction are also important. Part of 
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clinical stabilization might include starting an individual on buprenorphine or methadone, 
medications used to control opioid cravings and prevent withdrawal symptoms.21,22 









Figure 2. Substance use disorder treatment Continuum of Care Schematic.23 Access to recovery services generally 
follows this continuum. Harm reduction is a protective cushion that helps reduce the risks associated with substance use. Harm 
reduction is especially important if an individual falls out of care or relapses. Throughout the continuum, access to harm 
reduction services, medication for addiction treatment, and other supportive services are important for sustaining recovery.  
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Even if an individual is ready and willing to go to a detox program or CSS, they 
are constrained by bed availability. A data brief from the Bureau of Substance Abuse 
Services and Massachusetts Department of Public Health shows that the number of beds 
at each step in the continuum has increased over the past few years.24 Figure 3 shows the 
number of licensed treatment beds and enrolled individuals for the 2018 fiscal year. The 
graph shows that moving from ATS to TSS, the number of beds and enrolled individuals 
decreases. Given that the average length of stay increases going down the continuum, the 
number of weekly referrals to a subsequent program may be greater than the discharges.20 
Even though there are many more residential treatment beds than there are TSS beds, the 
residential beds are often occupied for months at a time. There is a need for low threshold 
services for individuals that fall out of treatment and return to using substances. Harm 
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Harm reduction encompasses a range of strategies meant to reduce the risks 
associated with drug use. These interventions and services are not meant to be separate 
from treatment, but are meant to keep individuals safe so they may continue accessing 
treatment, or seek treatment later. In the schematic of SUD treatment depicted by Figure 
2, harm reduction is depicted as a protective element, which shields an individual from 
some of the risks surrounding substance use. Examples of harm reduction services 
include naloxone distribution programs, syringe service programs (SSP), supervised 
consumption sites (SCS), and medical monitoring programs (MMP).  
Naloxone is a pharmacological agent used to reverse the respiratory depression 
and sedation during an opioid overdose. It acts by competitively binding to µ-opiate 
receptors in the central nervous system with high affinity.25 Naloxone distribution 
programs provide overdose response training and distribute resources to communities. 
There is evidence that these programs reduce rates of both fatal and non-fatal overdose in 
communities. 26,27 Analysis of recent prescribing trends revealed that Naloxone 
dispensing increased eight-fold from the end of 2015 to 2017.28 This corresponds to the 
approval of Narcan®, an intranasal formulation of Naloxone, in November 2015. The 
analysis shows that Narcan® has become the most widely prescribed form of Naloxone in 
recent years. However, there is evidence that the availability of Naloxone does not 
necessarily correspond to possession and use.29 Additionally, Naloxone does not address 
risks associated with intravenous drug use (IDU) such as syringe sharing and the 
transmission of Human Immunodeficiency Virus (HIV) and Hepatitis C.  
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A harm reduction intervention which specifically targets risks associated with 
IDU is syringe service programs. SSP exposure has been associated with a reduction in 
HIV transmission30, a reduction in improper disposal of syringes31,32, and increased 
likelihood of entering SUD treatment33. A cohort study following injection drug users in 
Seattle found that new SSP participants were 5 times more likely to enter (MMT) 
compared to those who have never engaged with a SSP.33 Their results also showed that 
current and former SSP participants were each 2.9 times more likely to enter MMT 
compared to those who have never engaged with a SSP. Syringe service programs are not 
limited to connecting participants to MMT, but have been shown to be an opportunity to 
connect to peer support services and other health education.34  
 Another harm reduction strategy which provides opportunities to engage with 
PWUD is supervised consumption sites, also referred to as supervised injection facilities. 
The first government-sanctioned SCS in North America, Insite, opened in Vancouver, 
Canada September 2003.35 Insite is co-managed by the Portland Hotel Society 
Community Services Society and Vancouver Costal Health. Located in Vancouver’s 
Downtown Eastside, Insite provides access to a clean and protected space for participants 
to consume drugs, as well as supplies required for preparing and consuming drugs.36 
Beginning in 2007, participants could access an in-house detox and transitional housing 
program, Onsite. The Vancouver SCS is staffed by health workers and clinicians who are 
trained in overdose intervention and skilled in connecting participants to SUD treatment. 
An examination of referrals shows that participants were referred to both medical and 
non-medical services such as: addiction counseling, community clinics, hospital 
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emergency, detox, community services, housing services, MMT, and recovery houses.37 
Weekly engagement with a SCS and any engagement with an addiction counselor were 
found to be associated with quicker entry into a detox program.38 Regular engagement 
with SCS and addiction counseling were also found to be independently associated with 
more rapid drug cessation.39 Analysis of overdose trends following the establishment of 
the Vancouver SCS found that fatal overdoses in the area around the SCS decreased by 
35%, compared to 9.3% in other areas in the city.40 Due to the many legal and social 
obstacles, there are currently no SCS operating in the United States.41 A Philadelphia 
based harm reduction organization, SafeHouse, found legal ground to move ahead in 
opening a SCS.42 However, they have yet to find a suitable location to operate.43  
 Medical monitoring programs are spaces where individuals who have consumed 
sedating substances can be observed and treated for drug overdose if necessary.44 They 
are distinct from SCS in that there is no consumption of illegal drugs on site. Participants 
enter the facility having already injected or ingested their drug. MMP are a harm 
reduction strategy that target individuals actively experiencing the effects of illicit drug 
use. They aim to reduce the incidence of fatal drug overdose. MMP also aim to reduce 
the burden of drug use on their surrounding neighborhood.44 
 
Supportive Place for Observation and Treatment 
Supportive Place for Observation and Treatment (SPOT) is a medical monitoring 
program opened by BHCHP in April 2016.45 It is located at BHCHP’s headquarters, in 
the South End neighborhood of Boston. SPOT runs Monday through Friday from 8:30am 
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to 5pm, and on Saturday from 9am to 4pm. The program is staffed by a registered nurse 
(RN) and a harm reduction specialist (HRS) who attend to 8-10 individuals at a time. 
They operate in a room set up with reclining chairs, continuous vital signs monitoring, 
and access to supplemental oxygen, intravenous fluids, and Naloxone if needed.45,46 In 
the event that a greater level of care is required, or an individual remains at a high 
sedation level towards the end of the facility hours, participants are transferred to the 
emergency department (ED).  Not only does SPOT strive to prevent fatal drug overdose, 
it also works to connect individuals to SUD treatment. In SPOT, the role of the HRS is to 
provide low-threshold overdose prevention support, and help facilitate referrals to SUD 
treatment.44 The HRS plays a vital role in building trusting relationships with SPOT 
participants, in hopes of creating honest dialogue and removing the stigma surrounding 
their drug use.45 Some of the risk reduction education that the HRS provides may include 
education on syringe and injection site hygiene, or reminding individuals not to use drugs 
alone. On top of providing services pertaining to substance use, SPOT also provides a 
safe environment that shields individuals from the dangers of being over-sedated in 
public. Some of these dangers include physical and sexual violence, theft, and exposure 
to hostile weather.45  
 
Study Aims 
 In order to assess the outcomes from SPOT, we conducted the following quality 
improvement study. One of the outcomes of interest is the ability for SPOT to connect 
participants to SUD treatment. The primary aim of the study is to examine the referrals to 
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SUD treatment directly from SPOT, and describe any factors associated with those 
referrals. The hope is to identify patterns in participant behavior that will help guide 
operational practices. More broadly, the hope is that the data described in our study might 
guide the development of other medical monitoring programs. As the state of 
Massachusetts looks to expand the number of low threshold addiction services and put a 
greater focus on harm reduction, the results of the analysis will be informative for the 
development of those programs. Given that SPOT is such a unique program and has 
seldom been described or replicated on a similar scale, the results and conclusions of the 
study will benefit both internal advancements, and other organizations hoping to manage 
similar programs. Finally, the data from this study and its implications about the efficacy 
of SPOT may be used as evidence to merit additional funding for the program, which 





Participants and Data Collection 
 Our study retrospectively analyzed SPOT visits made between April 26, 2016 
(day one of SPOT) and December 31, 2019. All SPOT participants were at least 18-
years-old. Participants were included if they had at least one visit that contained 
documentation of administered services. Those services could include monitoring, harm 
reduction counseling and education, or a referral to SUD treatment. Documentation for 
visits is recorded by SPOT nurses and harm reduction specialists on staff that day. A 
single participant may have contributed multiple visits to the dataset.  
In order to maintain participant privacy, SPOT uses an electronic medical record 
separate from the system used by BHCHP. At their first encounter, participants are given 
a unique identifier generated using a combination of personally identifiable information. 
However, individuals wishing to remain anonymous or are unable to provide information 
may still use SPOT. Due to varying staff throughout the week, a single participant may 
have been given multiple unique identifiers. These duplicates were identified by a SPOT 
staff member and reconciled by a BHCHP Data Specialist in the SPOT database. 
The dataset for this study was organized into Microsoft Excel workbooks, 
compiled from data exports from the SPOT electronic medical record. Each Excel 
workbook contained data pertaining to a specific variable of interest. Eligible participants 
and visits were identified and included in the final dataset. For the purpose of this study, 
participants who only used SPOT on the weekend were excluded. Anonymous 
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participants and those who did not provide a date of birth were excluded due to analytical 
limitations. All SPOT visits are identified with a randomly generated visit ID. 
All Excel workbooks and documents containing personally identifiable information were 
stored in a folder accessible only to the study team. To prevent data breaches and 
unintended sharing of confidential information, all analysis was done on a BHCHP 
computer or on the BHCHP network.   
 
Factors of Interest 
 Referrals to SUD treatment was the dependent variable for this study. Factors 
examined in this study fall into two groups, participant level factors and visit level 
factors. Participant level factors include gender, age, overdose history, and present 
substances. The visit level factors examined are whether health or harm reduction 
education was provided, and the maximum sedation level recorded during the a SPOT 
visit. These factors will be described in greater detail. 
 
Referral to Substance Use Disorder Treatment 
The purpose of analyzing referrals was to assess the ability of SPOT to connect its 
participants to treatment. For the purpose of this study, a referral to SUD treatment 
included any referral to detox, CSS, TSS, dual diagnosis programs (DD), OBAT, MMT, 
and the BMH if one of the goals for the respite stay was detox. Referrals were measured 
in two ways. The first measure was whether a participant or visit was associated with any 
referral to SUD. The second measure was the visit count prior to the first referral. The 
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goal of examining the visit count prior to the first referral is to identify any factors 
associated with how quick a participant connects to SUD treatment directly out of SPOT. 
For analytical purposes, we categorized visits as “rapid connection” if the first referral to 
SUD treatment was made within three visits, and “non-rapid connection” if the first 
referral was made within four or more visits.  
  
Participant Level Factors 
 Participant level factors were self-reported. This includes demographic 
information such as gender and age. Age was calculated by subtracting the participant’s 
date of birth from December 31, 2019, and then rounding down to the nearest whole-
year. Any participant that did not provide a date of birth, or the date of birth was entered 
incorrectly by a SPOT staff member, was excluded. Age was then divided by decade, 
with the exception of “18–29” and “60+”. Overdose history was self-reported or recorded 
by a SPOT staff member if they were present for the overdose response. Reported 
substances are collected from participants during their visit. From the data exports, 
reported substances were divided into opioids (heroin, Suboxone, methadone), non-
opioids with sedating properties (benzodiazepines, clonidine, promethazine, gabapentin), 
stimulants (cocaine, crack, methamphetamines), cannabinoids, and alcohol. Because of 
the prevalence of polysubstance use, reported substances was only examined at the 





Visit Level Factors 
 Visit level factors are documented by a SPOT staff member at each visit. This 
includes education, vital signs, and sedation level. Education refers to health and harm 
reduction education. We examined this factor in order to assess the effect of HRS 
engagement on SUD treatment referrals. Interventions, such as providing naloxone or 
advising a participant on injection site hygiene, are documented as education. Sedation 
level is recorded using the Inova Health System Acute Care Sedation Scale (ISS), which 
ranges from level 1–6 (Table 1).47 Sedation level is assessed by a nurse two or three times 
every hour. This study focused on the maximum sedation level reached during the course 
of each SPOT visit. Like with visit count to first SUD treatment referral, maximum 
sedation levels are divided into binary outcomes, where levels 1-4 are categorized as 
“light sedation” and levels 5–6 as “heavy sedation”.  
 
Table 1. Inova Sedation Scale  
Sedation Level Description 
1 Alert and oriented 
2 Calm, occasionally drowsy 
3 Drowsy, dozing intermittently 
4 Sleeping, easily aroused 






We created a Masterfile containing all eligible visit IDs and unique identifiers. 
This file was used to filter through Excel workbooks and eliminate ineligible entries. 
From each workbook, we counted and organized eligible visits and unique identifiers into 
cross tables. The cross tables included the factor of interest on one axis and the SUD 
treatment referrals on the other axis. For participant level factors, we made a second cross 
table where the outcome of interest was rapid or non-rapid connection to SUD treatment. 
From these cross tables, we calculated crude odds ratios along with corresponding 95% 
confidence intervals and p-values.  
 We used binary logistic regression models to analyze demographic variables 
(gender and age) and factors of interest together. Adjusted odds ratios were generated 
along with corresponding 95% confidence intervals and p-values.  
 All odds ratios and confidence intervals were calculated manually from the cross 
tables. Chi-square tests of independence were calculated in Microsoft Excel. The binary 
logistic regression modeling was performed in Microsoft Excel using the XLSTAT add-
in by Addinsoft. All p-values were calculated using Microsoft Excel, at a two-sided 




The final dataset for this study contains 844 eligible participants, who have a total 
of 12,723 visits and 829 referrals. The demographic distribution of the participants (Table 
2) are a majority male (64.3%) and between the ages of 30 and 49 (67.7%). The youngest 
participant is aged 19 and the oldest is aged 76. Of the eligible participants, 289 (34.2%) 
have at least one documented referral. Of the 829 referrals, 454 (54.8%) are to SUD 
treatment. There are 191 unique participants who have at least one referral to SUD 
treatment, which accounts for 22.6% of all eligible participants. Transgender participants 
account for 0.6% of all eligible participants. Of note, transgender participants do not 
contribute any referrals to SUD treatment to the dataset.   
 
Table 2. Gender and Age of All Eligible Participants  
 Gender  
Age Female Male Transgender Total 
18–29 43 54  97 
30–39 140 209 1 350 
40–49 61 156 4 221 
50–59 40 93  133 
60+ 12 31  43 






For the study analysis, referrals were categorized into a binary outcome of 
whether they were to SUD treatment or not. However, when describing referrals 
altogether, they actually fall into many different categories. Broadly, referrals can be 
divided into three categories, which are SUD treatment, other health services, and social 
services. Within those categories, referrals can subdivide into more specific services 
(Table 3). Referrals to SUD treatment were defined previously, and include services such 
as detox and OBAT. Other health services encompass all healthcare related services that 
do not directly address SUD. This includes referrals to primary care and behavioral health 
services. It also includes referrals to BMH where detox was not a primary goal of the 
inpatient stay. The distinction between “BMH Detox” and BMH – Other Health Services 
was made by the HRS or nurse facilitating the referral. Referrals to social services are not 
strictly referrals in the sense that the participant is being directed towards another facility 
or organization, such as connecting them to the Social Security Benefits Coordinator at 
BHCHP. The social services category also includes services provided directly by a HRS 
or nurse, such as providing the participant with a voucher to acquire a new identification 
card. Housing services also falls into the social services category. However, it is given its 





Table 3. All Referrals Initiated from SPOT  
Referral Type Count of Referrals 




Dual Diagnosis 3 





Other Health Services 308 
Shelter 3 







 Referrals to the emergency department included in Table 3 do not account for 
drug overdose. These ED referrals were to address acute health concerns such as 
infection, injury, or a need for urgent psychiatric care. The continuity category is meant 
to capture work done by a SPOT staff member to help participants maintain or access 
SUD treatment. Many continuity referrals involve staff assisting participants with 
transportation to a treatment facility, where the connection to treatment was completed 
outside of SPOT. Another example of a continuity referral would be a SPOT staff 
member advocating for a participant by contacting their treatment provider through 
phone or a letter. Similar to continuity, the shelter category includes instances where a 
SPOT staff member advocated for a participant so that they may maintain access to 
shelter services.   
 
Count of Visits to First Substance Use Disorder Treatment Referral 
 For the 191 unique participants with at least one referral to SUD treatment, we 
counted the visits prior to the first referral initiation. This was done to assess how quickly 
SPOT was able to connect participants to treatment, and examine factors associated with 
rapid and non-rapid connection. A rapid connection is defined as occurring within 1-3 
visits, and 4 or more visits for non-rapid connection. The values for the count range from 



























 The mean count of visits is 11.4 (95% confidence interval: 8.5–14.3), and the 
median is 4 visits. As shown by Figure 4, the count of visits is skewed towards lower 
values. The frequency of counts begins to drop off after four visits. To account for the 
wide range of values and the diminishing frequency as values increase, the analysis of the 
count of visits uses a binary outcome of rapid or non-rapid connection to treatment. A 
total of 92 (48.2%) participants have a rapid connection to SUD treatment, whereas 99 
(51.8%) participants have a non-rapid connection to treatment. 
 
Demographic Factors 
 There are 68 female participants and 123 male participants with at least one 
referral SUD treatment. Transgender participants do not contribute any referrals to 
treatment. The proportion of female and male participants with at least one referral to 
treatment are very similar for both genders, 0.230 and 0.228 respectively. A chi-square 
test of independence indicates there is no significant difference in the two proportions, 
with a p-value of 0.916. An odds ratio calculation results in a similar conclusion, where 
the odds of male participants compared to female and transgender participants of having 
a referral to SUD treatment is 1.00 (95% confidence interval: 0.72–1.41, p-value 0.40). In 
our sample, male or female gender is not associated with different odds of having a 
referral to SUD treatment.  
 Similar calculations are performed when examining the relationship between 
gender and how quickly a participant was connected to SUD treatment from SPOT. The 
proportion of female participants with a rapid connection to treatment is 0.38, compared 
	
28 
to 0.54 for male participants. A chi-square test of independence yields a p-value of 0.04, 
which indicates a statistically significant difference between the two genders. An odds 
ratio calculation of male participants with rapid connection versus female participants 
reveals that male participants have higher odds of rapid connection (odds ratio 1.87, 95% 
confidence interval 1.02–3.42, p-value 0.05).  
 The same analysis is done for the different age groups. Tables 4a and 4b 
summarize the odds ratios for having a referral to SUD treatment, and a quick connection 
to treatment. A chi-square test of independence is conducted to compare each age. 
Calculations reveal a statistically significant difference between the proportion of 
treatment referrals (p-value 0.04). Odds ratio analyses reveal only a single statistically 
significant result, which is that the 30–39 age group have higher odds of connecting to 
SUD treatment from SPOT (odds ratio 1.42, 95% confidence interval 1.03–1.97, p-value 
0.04). The 60+ age group do not have any rapid connections to treatment, thus odds ratio 




Table 4a. Age Groups and Connecting to Substance Use Disorder Treatment 
Age Odds Ratio 95% Confidence 
Interval 
p-value 
18-29 1.22 0.75–1.98 0.29 
30-39 1.42 1.03–1.97 0.04 
40-49 0.93 0.64–1.35 0.37 
50-59 0.60 0.36–0.98 0.05 
60+ 0.44 0.17–1.12 0.09 
 
Table 4b. Age Groups and Rapid Connections to Substance Use Disorder Treatment 
Age Odds Ratio 95% Confidence 
Interval 
p-value 
18-29 1.19 0.51–2.77 0.37 
30-39 1.25 0.71–2.21 0.29 
40-49 0.63 0.32–1.22 0.16 
50-59 1.87 0.74–4.75 0.17 
60+ X X X 




Participant Level Factors 
 
Overdose History 
 Overdose history and reported substances are the other participant level factors 
examined along with demographics. The sample contains 70 unique participants with a 
documented overdose history. Of those 70 participants, 52 have a single documented 
overdose and 18 have multiple documented overdoses. We use chi-square tests of 
independence to examine the relationships between overdose history and participant 
connection to SUD treatment, as well as rapid connection to treatment. The results for 
both tests show a statistically significant difference between participants with and without 
an overdose history (p-value < 0.0001 for both tests). We employed logistic regression 
modeling to analyze demographic factors alongside overdose history. The resultant 
adjusted odds ratio calculations reveal that participants with an overdose history have 6.6 
times the odds of connecting to SUD treatment from SPOT (Table 5a), compared to those 
who did not have a documented overdose history. However, a documented overdose 
history is negatively associated to rapid connection to treatment, with an adjusted odds 
ratio of 0.42 (Table 5b). Thus, while participants with a documented overdose history 
have increased odds of connecting to SUD treatment, they tend to require more visits 
before the first referral is placed. 
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6.48 3.87–10.86 < 0.0001 6.59 3.92–11.09 < 0.0001 
  


















0.46 0.22–0.93 0.04 0.42 0.20–0.88 0.03 




 A list of consumed substances are collected at each visit if possible. The dataset 
contains 1346 eligible visits where at least one substance was reported, which accounts 
for 402 unique participants. A single participant may have contributed multiple times to 
that visit count. In fact, 93 unique participants contributed 10 or more times to the count 
of reported substances. Of those 1346 visits, reported polysubstance use is more common 
than report of a single substance. There were 445 (33.0%) instances where only a single 
substance was reported compared to 901 (67.0%) instances where multiple substances 
were reported. Of the 402 unique participants with documented substances, only 134 
(33.3%) have at least one referral to SUD treatment. The most reported substance is 
Klonopin, followed closely by clonidine and heroin (Table 6). Substances are grouped 
together into broader categories for analysis. The category with the most instances is non-
opioids with sedating properties (other sedating substances), and the category with the 
least instances is alcohol. It should be noted that SPOT was not designed to monitor 
individuals sedated from alcohol, which explains the low instance of reported alcohol. 
 We use chi-square tests of independence to compare a report of a substance 
category versus no report of that substance category, and its association with referrals to 
SUD treatment. The only substance that does not reach the critical value for statistical 
significance is alcohol (Table 7a). To examine any associations between the medication 
cocktail and referrals to SUD treatment, we combined counts for opioids and other 




Table 6. List of Reported Substances 































 We only analyzed reported substances at the participant level. A participant is 
counted in a substance category if they had any report of that substance at a SPOT 
encounter. Crude odds ratios are calculated for each substance category. Any reported 
stimulant use is associated with the highest odds (crude odds ratio 2.96) of connecting to 
SUD treatment from SPOT (Table 7a). Opioids and the combined category of opioids and 
other sedating substances have similar crude odds ratios to each other, 2.05 and 2.02 
respectively. However, the combined category of opioids and other sedating substances 
has a narrower 95% confidence interval and smaller p-value. Logistic regression 
modeling is used to assess the relationships between each substance category along with 
demographic factors. The combined opioids and other sedating substances category was 
excluded from the model so as to not double count values. Report of alcohol or stimulant 
use both have the highest adjusted odds ratio of about 2.6. However, the confidence 
interval for reported alcohol does not reach statistical significance (p-value 0.07), while 
the confidence interval for reported stimulants does (p-value < 0.0001). 
 Analysis of how quickly participants were connected to SUD treatment from 
SPOT did not yield very reliable results. We used the same calculation and statistical 
models to assess any association between reported substances and a rapid versus non-
rapid connection to treatment. Chi-square tests of independence could not be performed 
for cannabinoids or alcohol because their expected values do not reach the minimum 
value. Additionally, standard error values for the calculated odds ratios are quite large, as 
indicated by the corresponding p-values (Table 7b). None of the substance categories 





Table 7a. Reported Substances and Connecting to Substance Use Disorder Treatment 
Substance p-value (Chi-






















0.001 2.02 1.32–3.11 0.002 X X X 
Stimulants < 0.0001 2.96 1.80–4.87 < 0.0001 2.61 1.53-4.44 < 0.0001 
Cannabinoids 0.03 1.98 1.05–3.72 0.04 1.71 0.86–3.41 0.13 
Alcohol 0.10 2.08 0.84–5.12 0.11 2.62 0.94–7.28 0.07 




Table 7b. Reported Substances and Rapid Connections to Substance Use Disorder Treatment 
Substance p-value (Chi-






















0.69 0.86 0.42–1.77 0.37 X X X 
Stimulants 0.98 1.01 0.42–2.40 0.40 0.99 0.39–2.50 0.40 
Cannabinoids X 0.95 0.27–3.35 0.40 0.97 0.26–3.69 0.40 
Alcohol X 1.98 0.38–10.21 0.29 1.84 0.32–10.61 0.32 
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 Adjusted odds ratios calculated from values generated from the logistic regression 
do not provide any more clarity into the relationship between reported substances and 
rapid connection to treatment. Reported alcohol use has the highest adjusted odds ratio 
(1.84). However, the range of its confidence interval is quite large and the corresponding 
p-value does not reach statistical significance. Reported stimulant use was the best 
indicator for connecting to substance use referral treatment; but, when examining its 
association with a rapid connection to treatment, there does not appear to be an 
association.  
 
Visit Level Factors 
 The two visit level factors analyzed in this study are health and harm reduction 
education and maximum sedation level. Documented education is used as a stand-in for 
HRS interaction during a SPOT visit. The hope is that connecting with the HRS improves 
participant outcomes. There are 4634 eligible visits where education was documented, 
323 (7.0%) of which resulted in a referral to SUD treatment. The eligible visits with 
documented education correspond to 559 unique participants, with 177 participants 
having at least one referral to treatment.  A chi-square test of independence indicates that 
there is a statistically significant difference between the referral outcomes for 
documented education compared to no documented education (p-value < 0.0001). A 
crude odds ratio calculation reveals that visits with documented education have 5.54 
times the odds of resulting in a referral to SUD treatment compared to visits with no 
documented education (Table 8). Thus, interacting with a HRS is associated with 
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increased odds of a participant being referred to treatment.   
 Sedation level was measured using the ISS, which ranges from levels 1-6. It is 
recorded at every SPOT visit if a participant is monitored. There are 272 (2.1%) visits 
that correspond to a referral to SUD treatment. No visits which reached a maximum 
sedation level of 6 resulted in a referral to SUD treatment. We grouped together sedation 
levels into binary outcomes. Levels 1-4 are considered lightly sedated, while levels 5-6 
are considered heavily sedated. We performed a chi-square test of independence 
comparing the referral outcomes for the two sedation groups. The proportions of 
treatment referrals are statistically significant different (p-value < 0.0001). A crude odds 
ratio calculation reveals that visits where a participant is heavily sedated has 0.45 times 
the odds of resulting in a referral to SUD treatment (Table 8).  
 We used logistic regression modeling to examine demographic factors and visit 
level factors together. Additionally, both education and maximum sedation level were fit 
together in the same model. The resultant adjusted odds ratios illustrate the effect of both 
visit level factors on connecting to substance use treatment at the same time. The adjusted 
odds ratios lead to the same conclusions; that documented education increases the odds of 


















Education 5.54 4.44–6.91 < 0.0001 5.14 3.93–6.71 < 0.0001 
Heavy 
Sedation 0.45 0.31–0.64 < 0.0001 0.55 0.38–0.79 < 0.0001 
*bold values indicate statistically significant results 
 
Summary  
 The study analysis reveals that many factors are associated with increased or 
decreased odds of a participant connecting to SUD treatment directly from SPOT. Gender 
and age do not show any significant association to a connection to treatment. Overdose 
history, reported stimulant use, and documented health or harm reduction education are 
all associated with increased odds of being referred to SUD treatment. Heavy sedation is 
associated with decreased odds of a treatment referral. When looking at factors associated 
with rapid connection to treatment, male gender is associated with increased odds, while 






 The results of our quality improvement study helps to shed some light on the 
behavior of SPOT participants. Many of the study outcomes are intuitive, but are 
validating of the work being done each week by a SPOT staff member. The fact that 
documented education, and thus documented interaction with a HRS, resulted in a five-
fold increase in the odds of connecting to SUD treatment is evidence that the work done 
by the SPOT HRS is impactful. The association between reported overdose history and 
increased odds of connecting to treatment indicates that a SPOT staff member is 
successful in supporting some of the highest risk individuals that utilize the program. 
Even the association between heavily sedated participants and decreased odds of 
connecting to SUD treatment may support the notion that HRS connections lead to 
increased referrals to treatment. If an individual is asleep of unconscious, they are unable 
to engage in harm reduction education or explore treatment opportunities. If the 
participant is new to SPOT, heavy sedation may hinder the formation of meaningful 
connections with staff.  
 The other outcome of interest in our quality improvement study was the speed at 
which participants are connected to SUD treatment. Male gender is associated with 
almost double the odds of rapid connection to treatment compared to the rest of the study 
sample. In order to address this discrepancy, it would be helpful to follow up with a more 
robust study to identify and describe barriers to treatment that disproportionately affect 
women. In recent years, BHCHP has expanded services for women, including the HER 
(Health Empowerment Resources) Saturday Clinic, and providing behavioral health 
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services at the Woods Mullen Shelter. SPOT may benefit from employing strategies that 
specifically target women. 
 The other significant result from the examination of rapid connections to 
treatment is that reported overdose history is associated with decreased odds of a referral 
to treatment within 1-3 visits. That means that while participants with a reported overdose 
history have increased odds of a referral to SUD treatment, they tend to take longer to 
connect to those services. This result may be due to behavior associated with individuals 
with reported drug overdoses that the study does not take into consideration. 
Additionally, this result may be heavily influenced by a limitation in study analysis, 
which does not consider temporal factors. This limitation will be discussed further in a 
following section.  
 The analysis of reported substances supports many observations already known to 
BHCHP and those who work in SUD treatment. The increasing prevalence of 
polysubstance use is reflected in the substances reported by SPOT participants. Three of 
the four highest reported substances, Klonopin, clonidine, and Neurontin, are non-opioids 
commonly combined in a medication cocktail. Regarding the outcomes of interest, the 
most significant result from the referrals analysis is that any report of stimulant use was 
associated with the highest odds of connecting to SUD treatment. This suggests that there 
are behaviors associated with stimulant use that could be illuminated in future studies.  
 The two most impactful factors examined in this study, education and overdose 
history, suggests that one of the strengths of SPOT is its ability to engage with PWUD. 
This means that one way to improve outcomes is to expand the program’s ability to build 
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and maintain connections with at-risk individuals. This does not need to be limited to 
recruiting more HRS for the program, but can also include peers. Another way that the 
program can increase engagement would be to increase its outreach capabilities. An 
example of this would be maintaining connections with individuals after they have 
entered a treatment facility. This does not directly line up with SPOT’s model of 
addressing immediate harm reduction needs; however, it may be something to consider 
elsewhere in BHCHP or with a partnering organization. One of the strengths of BHCHP 
is its ability to come up with creative solutions to problems. BHCHP already co-manages 
the CareZone Van, a mobile clinic meant to outreach to individuals that aren’t utilizing 
brick and mortar facilities for SUD treatment.48 Our study shows that very low threshold 
interventions such as SPOT, and now the CareZone Van, are effective in helping 
individuals access the SUD continuum of care. There needs to be a concerted effort by 
the state of Massachusetts and healthcare organizations to provide lower threshold 
opportunities to connect to care.  
 This quality improvement study is just an initial look into the data collected by 
SPOT. Additional questions and factors of interest arose as the study progressed. One 
variable that would be impactful to quantitatively analyze is the ability of SPOT to help 
participants maintain access to health and social services. The concept of continuity was 
briefly discussed in the referrals analysis; however, the extensive work done by a SPOT 
staff member to help participants overcome barriers to care deserves to be examined 
more in detail. Another analysis of interest is to look at factors associated with successful 
referrals. Our current study only takes into account referral initiation, but does not 
	
43 
consider whether the participant received the services they were referred to. For example, 
a referral to detox does not mean that a participant ends up at a detox facility. If there are 
no available beds or if the participant changes their mind later in the day, the referral 
would not be considered successful. Ideally, the study would be a prospective cohort 
study that follows a group of participants as they access the SUD continuum of care.   
 
Limitations 
  The quality improvement study we conducted had a number of limitations ranging 
from data collection to the analysis. The study relied on self-reported factors, such as 
reported substances. The list of reported substances may not be completely accurate if 
participants had difficulty recalling or did not wish to be truthful about the substances 
they consumed. Another limitation in data collection was that the electronic medical 
record in which SPOT documentation occurs is not very sophisticated, and not designed 
for streamlined reporting. Many of the data exports had to be manually reviewed and 
corrected, which leaves the possibility of inaccuracies in the data. Additionally, there is 
some question as to how certain values are entered and stored in the SPOT database. One 
example would be SPOT admit and discharge date-time. Initially, a factor of interest was 
visit length. However, there were many discrepancies in the admission and discharge 
times that put all of the date-time values into question. Visit length may be reexamined 
later, as SPOT is currently in the process of migrating to a new electronic medical record 
system. A lack of data also limited the analyses that could be performed. Another factor 
that had to be excluded from the study was the administration of supplemental oxygen. 
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There were not enough visits where supplemental oxygen was administered that also 
corresponded to a referral. Preliminary calculations resulted in very large standard error 
values that did not merit further examination. It is likely that this issue could have been 
addressed using a more sophisticated statistical model.  
 The most significant analytical limitation in this study was the measure we used 
to evaluate how quickly a participant connected to treatment. The issue with using the 
visit count before initiation of the first referral to SUD treatment is that it does not take 
into account the time between visits. This means that a referral initiated on the third visit 
would be considered rapid even if the three visits occurred over the course of a year, 
whereas a referral placed on the fourth visit would be considered non-rapid even if all 
four visits occurred in the same week. A measure or statistical model, which factors in 
the time between visits would yield more accurate conclusions about SPOT’s ability to 
rapidly connect individuals to treatment.  
 Given the many limitations encountered during this quality improvement study, 
we hope that the results of our study may serve as a starting point and guide for more 
robust studies if additional funding and resources become available.   
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